A Single-centre Phase III Clinical Trial for Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Produced by Shandong Hengye Biotech Co., Ltd. in Healthy Chinese Infants Aged 6-11 Months, Aimed to Evaluate Immunogenicity and Safety

Trial Profile

A Single-centre Phase III Clinical Trial for Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Produced by Shandong Hengye Biotech Co., Ltd. in Healthy Chinese Infants Aged 6-11 Months, Aimed to Evaluate Immunogenicity and Safety

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Japanese encephalitis vaccine (Primary)
  • Indications Japanese encephalitis
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Most Recent Events

    • 30 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 01 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top